{"id":"aph-1501","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It is being investigated for its potential therapeutic effects through interaction with the endocannabinoid system. The exact mechanism of action is not well understood at this time.","oneSentence":"APH-1501 is a cannabinoid-based therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:46.411Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant epilepsy"}]},"trialDetails":[{"nctId":"NCT03813095","phase":"PHASE2","title":"Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction","status":"UNKNOWN","sponsor":"Aphios","startDate":"2023-10","conditions":"Addiction, Opioid Dependence, Opioid Withdrawal","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"APH-1501","genericName":"APH-1501","companyName":"Aphios","companyId":"aphios","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APH-1501 is a cannabinoid-based therapy. Used for Treatment-resistant epilepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}